The functionality and developability properties of therapeutic antibodies are two major concerns in preclinical development. Addressing the optimization strategy in the discovery stage enables acquiring better antibody candidates before entering CMC.

Empowered by a well-established bioinformatics platform, ProBio offers comprehensive antibody engineering services, including humanization, affinity maturation, Fc engineering, and developability optimization, to obtain "me-better" antibody leads.

In addtion, ProBio offers 3 developability assessment packages for antibody drug candidates at different discovery stages to identify the potential risks of manufacture and clinical failure. The webinar will cover integrated antibody engineering and developability assessment platforms by ProBio to expedite the drug discovery process.